Kornimate/medical-research-clean huggingface dataset:
does single dose imipramine affect the opening pressure of the urethral and anal sphincter?

Conditions: Urinary Incontinence, Stress; Fecal Incontinence

Summary: a double-blinded, randomized, crossover study in healthy females with placebo and single dose imipramine 50 mg. primary objective: does imipramine increase the tone of the external urethral sphincter? urethral opening pressure (uop) is measured with urethral pressure reflectometry (upr). uop increases correlate with effect in treating stress urinary incontinence. can imipramine treat stress urinary incontinence? secondary objective: does imipramine increase the tone of the anal sphincter? the opening pressure is measured with anal acoustic reflectometry (aar). the investigators also wish to establish the within-subject standard deviation for aar to enable power calculations in future studies.


Eligibility criteria:
inclusion criteria: * signed consent form. * healthy. * female. * non-smoker. * age 18 to 55, both inclusive. * normal weight: bmi 19.5 to 30.0 kg/m2. weight minimum 50 kg. * no breastfeeding. * no pregnancy during the study. * no other clinical trials during the study. exclusion criteria: * known allergy to imipramine or any of the other known constituents. * medical history with significant cardiovascular, gastrointestinal, endocrinologic, hematologic, immunologic, metabolic, genitourologic, dermatologic, psychiatric, neurologic or dermatologic disease, lung disease, kidney disease, malignant disease or other significant diseases as assessed by the investigator. * medical history of urinary incontinence. * infectious disease 1 week prior to study day 1 or study day 2. * clinically significant findings during the physical examination. * pregnancy. * heart rate \ 100 beats per minute. mean systolic blood pressure \> 140 mmhg or mean diastolic blood pressure \> 90 mmhg (mean of the measures on the screening day). * prescription, over the counter or herbal medication two weeks prior to study day 1 or study day 2. excluding paracetamol and excluding oral contraceptives. * smoking 3 months prior to study day 1 or study day 2. * alcohol abuse, meaning \> 14 units (12 g alcohol) per week within three weeks prior to study day 1 or study day 2. * drug abuse 3 months prior to study day 1 or study day 2. * any condition as assessed by the investigator.
internet treatment for persons with overweight or obesity

Conditions: Overweight and Obesity

Summary: overweight and obesity are increasing and more than 50% of all people over 18 years in sweden are overweight or obese. main causes are changes in lifestyle habits regarding diet and physical activity. obesity increases the risk of various diseases such as type 2 diabetes, cardiovascular disease, arthrosis and cancer; it also affects the quality of life. losing 5-10% of body weight can improve metabolic health and quality of life. however, weight loss is difficult to achieve and especially to maintain over a longer period of time. treatment based on cognitive behavioral therapy improves long-term outcomes. a behavioral treatment program via the internet has been developed that contains 12 treatment modules that the patient follows for 6 months. the patient has regular contact with a therapist who follows the patient's treatment process and provides support. the purpose of this pilot study is to evaluate the internet-based treatment regarding weight reduction, change in eating habits, physical activity and quality of life. we also intend to investigate how feasible and user-friendly the treatment program is and the patients' experiences of the treatment effects.


Eligibility criteria:
inclusion criteria: * 18 years and older * bmi 30 or over * bmi over 28 and under 30 with one or more of the following: hypertension, prediabetes, type 2 diabetes, coronary heart disease, hyperlipidaemia, liver steatosis, sleep apnea or polycystic ovary syndrome exclusion criteria: * severe mental illness * previous or present eating disorder * pregnancy * breast feeding * serious cancer under treatment * use of weight-loss drugs * weight loss treatment in the last 6 months * misuse of alcohol or drugs * type 1 diabetes * not being able to speak/read/write swedish

Keywords: overweight obesity body weight
limited versus no-limited shoulder movement in breast cancer surgery

Conditions: Breast Neoplasms

Summary: randomized clinical trial that will include women aged 18 or older, submitted a curative surgery for breast cancer at hospital do câncer iii (hciii-inca). patients will be allocated into two groups: intervention (upper limbs no-limited movement with amplitude above 90º for flexion and abduction of shoulder) and control (upper limbs limited movement at maximum 90º amplitude flexion and abduction of shoulder, until withdrawal surgical points). sociodemographic and clinical data will be collected through interviews, questionnaires and electronic and physical records. the outcomes will be incidence of operative wound complications, like edema, joint restraint, winged scapula, pain, axillary web syndrome through the physical examination, performed by the nursing and physiotherapy team throughout the intervention period, ending in the 30-day post-operatory.

breast cancer treatment has been accompanying advances in technology, surgeries are more conservative, however postoperative complications are still observed. at early postoperative period, the most common operative wound complications are seroma, infection and necrosis. shoulder dysfunctions are a frequent complication and difficult women to return to their activities. there is no consensus regarding the onset and type of exercise in postoperative period. thus, the objective of this study is to compare the active no-limited mobilization with limited mobilization in the immediate post operatory at the incidence of wound complications in women submitted to surgery for the treatment of breast cancer. it's a randomized clinical trial that will include women aged 18 years or older, submitted a curative surgery for breast cancer at hospital do câncer iii (hciii-inca) located in rio de janeiro. all patients admitted for surgical treatment at the institution and during the study period will be evaluated for eligibility criteria. those considered eligible for the study will be clarified regarding the objectives, treatment groups, adverse effects and non-compulsory participation of the study. upon acceptance to participate, they will be allocated to the respective intervention groups. group 1 - upper limbs no-limited movement with amplitude above 90º for flexion and abduction of shoulder; group 2 - upper limbs limited movement at maximum 90º amplitude flexion and abduction of shoulder, until withdrawal surgical points.

Eligibility criteria:
inclusion criteria: * women aged 18 and over; * indication of curative surgical treatment for breast cancer axillary approach at hospital do câncer iii / inca. exclusion criteria: * bilateral breast cancer; * surgical treatment and / or previous radiotherapy for breast cancer; * reconstruction surgery; * functional alteration in upper limbs prior to diagnosis of breast cancer; * illiterate women who are not able to read and complete the protocol of adhesion; * women who are not able to answer questions clearly; * age over 80.

Keywords: exercise
a clinical study about improvement of chronic fatigue after taking red ginseng

Conditions: Chronic Fatigue Syndrome

Summary: the purpose of this study is to verify the efficacy of taking red ginseng for chronic fatigue patient.

verify the efficacy and safety after taking red ginseng for chronic fatigue syndrome or idiopathic chronic fatigue patient. they were verified through not only survey like vas change about fatigue, fatigue severity scale, chalder fatigue severity questionnaire, sri-short form , bdi , isi eq-5d-5l, ginseng subjective symptoms questionnaire but also an anti-oxidant test and a salivary cortisol test after 6 weeks after taking red ginseng or placebo drugs.

Eligibility criteria:
inclusion criteria: 1. at least 19 years of age, but below 65 years of age 2. a subject who appear repetitive or continuous fatigue of unknown cause. 3. a subject who has not abnormal findings of blood pressure, complete blood cell count(hb, hct, wbc, glucose), biochemical examination(ast, alt, creatinine), thyroid gland function test(tsh, ft4), urine test(urine glucose, urine protein), chest x-ray, and ecg for causing fatigue 4. a subject who voluntarily agrees to participate and signs after listening to explanation for purpose and characteristic about this clinical trial exclusion criteria: 1. a subject who has history or pi for chronic fatigue 2. a subject who takes this drug in 2 weeks : antidepressant drug, anti-anxiety drug,sleeping pill, an antihistamine etc. 3. pregnant, lactating women or a subject who has plan pregnancy. 4. a subject who receive medical treatment or takes dietary supplement(vit b,c etc) for chronic fatigue in 2 weeks. 5. a subject who has night duty, shift work or heavy work 6. a subject who is judged as being not fit by a specialist

Keywords: chronic fatigue syndrome idiopathic chronic fatigue red ginseng cortisol anti-oxidant
drug-drug interaction study between edp-305, fluconazole and quinidine in healthy volunteers

Conditions: NASH - Nonalcoholic Steatohepatitis

Summary: this is a non-randomized, 2-part, open-label, drug-drug interaction (ddi) study to evaluate the effect of concomitant administration of fluconazole or quinidine on the pharmacokinetics and safety of edp-305 in healthy human volunteers.


Eligibility criteria:
inclusion criteria: * an informed consent document signed and dated by the subject. * healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive. * female subjects must be of non-childbearing potential. exclusion criteria: * clinically relevant evidence or history of illness or disease. * pregnant or nursing females. * history of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection. * a positive urine drug screen at screening or day -1. * current tobacco smokers or use of tobacco within 3 months prior to screening. * any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy). * history of regular alcohol consumption. * participation in a clinical trial within 30 days prior to the first dose of study drug. * clinically significant electrocardiogram abnormalities or qtcf greater than 450 ms for males and 470 ms for females at either screening or day -1 (part 2 only), or any prior history of qt abnormality. * for part 2 subjects, the following cardiovascular abnormalities * qrs duration \>110 ms * incomplete right bundle branch block or any complete bundle branch block * heart rate \ 90 beats per minute (per vital sign capture while rested) * history of unexplained syncope, structural heart disease, or clinically significant arrhythmias * personal or family history of long qt syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or brugada syndrome * pr interval \>220 ms or any 2nd or 3rd degree av block * ventricular pre-excitation

Keywords: drug-drug interaction
effects of different anesthesia on odor memory

Conditions: Smell Functions; Odor Memory

Summary: this study aimed to research the effect of different general anesthesia administration on postoperative smell functions and memory.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) i-ii risk groups * operated under elective conditions with general anesthesia requiring intubation * operation durations of 40-180 minutes. exclusion criteria: * intracranial, * endocrine or nasal surgery, * pregnant cases, * those with history of respiratory tract diseases and psychiatric disease, with disorder of odor reception and perception, * with smoking and chronic alcohol use, * requiring a nasogastric probe

Keywords: general anesthesia management propofol sevoflurane odor memory smell functions
evaluation of the patient's experience in medical studies for cholangiocarcinoma

Conditions: Cholangiocarcinoma

Summary: the main reason for conducting this research is to gain a better understanding of why some people with cholangiocarcinoma are not able to participate in or complete clinical trials. historically, certain groups of people have been more likely to participate in clinical trials, but there hasn't been much research to understand why this is the case. the goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. the data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future cholangiocarcinoma patients during clinical trials.


Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age * participant has a diagnosis of cholangiocarcinoma * patient has self-identified as planning to enroll in an interventional cholangiocarcinoma clinical trial * patient must provide written informed consent exclusion criteria: * no diagnosis of cholangiocarcinoma confirmed * inability to perform regular electronic reporting * women who are pregnant, intend to become pregnant, or are lactating * patient does not understand, sign, and return consent form

Keywords: cholangiocarcinoma
effect of sodium concentration of priming and rinsing fluids on weight gain

Conditions: Fluid Overload and Hypertension in Hemodialysis Patients

Summary: sodium loading during hemodialysis treatment is common and may contribute to increased interdialytic weight gain and hypertension. excessive use of isotonic saline (containing 0.9% sodium chloride) is one of the factors that may cause sodium loading. during each hemodialysis session, approximately 400 ml of isotonic saline fluid, representing 1.4 grams of sodium, is used to prime and rinse the extracorporeal circuit, and is often administered to the patient. switching to a non sodium-containing priming and rinsing fluid could allow for removal of the equivalent amount of sodium. switching to a non sodium-containing solution for the priming and rinsing of the extracorporeal circuit can contribute to increased sodium removal during the dialysis treatment and allow for reduced interdialytic weight gain, reduced thirst, and improved blood pressure control.

this 12 week study consists of 3 phases: phase 1 (4 weeks): observation only. standard priming/rinsing procedure with isotonic saline phase 2 (4 weeks): intervention. switch to a 5% dextrose solution for priming/rinsing procedure phase 3 (4 weeks): switch back to standard priming/rinsing procedure with isotonic saline during the study, blood pressures will be measured in a standardized manner at 2 week intervals, a thirst questionnaire will be completed at the end of each phase, and interdialytic weight gain, in-center pre/post-hd blood pressure and intradialytic symptoms will be recorded, apart for routinely measured parameters.

Eligibility criteria:
inclusion criteria: * ambulatory, clinically stable maintenance hd patients on a thrice weekly hd regimen. * willing and able to provide written, signed informed consent after the nature of the study has been explained. * willing and able to comply with all study procedures. * age ≥18 years. exclusion criteria: * diabetes mellitus * considerable residual renal function (diuresis \> 500 ml/day) * simultaneous participation in another clinical study except observational trials * any psychological condition which could interfere with the patient's ability to comply with the study protocol * expectation that native kidney function will recover * impossibility to perform a blood pressure measurement on the upper limb * unable to verbally communicate in english * scheduled for living donor kidney transplant, change to peritoneal dialysis, home hd or plans to relocate to another center during the study period. * life expectancy \< 6 months

Keywords: sodium hypertension fluid overload hemodialysis dialysate interdialytic weight gain intradialytic hypotension
clonidine and morphine in caudal anesthesia

Conditions: Postoperative Pain

Summary: hypothesis: the combined use of clonidine and morphine in caudal anesthesia provides better postoperative analgesia than either drug alone after urogenital pediatric surgery.

it is a randomized, double blind study, involving 80 children with ages from 1 to 10 years old, submitted to urogenital surgery, under general anesthesia and caudal block. the patients will be divided into 4 groups: bupivacaine alone, bupivacaine plus clonidine, bupivacaine plus morphine, bupivacaine plus clonidine and morphine. the peroperative consumption of analgesics and inhaled gases, bis, heart rate and arterial blood pressure will be recorded. postoperative pain will be evaluated by using wong-baker faces scale and pain and discomfort score scale, as well as the consumption of analgesics.

Eligibility criteria:
inclusion criteria: * urogenital pediatric surgery * status physical(asa) 1 and 2 exclusion criteria: * cutaneous infection in puncture site

Keywords: caudal anesthesia, clonidine, morphine, bupivacaine
continuous and pulsed ultrasound treatments on carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the aim of this placebo-controlled study was to evaluate the effects of pulsed and continuous ultrasound treatments combined with splint therapy on patients with mild and moderate idiopathic carpal tunnel syndrome

the study included 36 carpal tunnel syndrome patients who were randomly divided into 3 groups.the first group received 0 w/cm2 placebo ultrasound treatment. second group received 1.0 w/cm2 continuous ultrasound treatment and the third group received 1.0 w/cm2 1:4 pulsed ultrasound treatment 5 days a week for a total of 15 sessions. all patients were also treated with night splints during the treatment. pretreatment and posttreatment visual analogue scale scores, symptom severity scale scores, functional status scale scores, median nerve motor conduction velocity. and distal latency and sensory conduction velocity of median nerve in the 2nd finger and palm were compared.

Eligibility criteria:
inclusion criteria: * mild or moderate idiopathic carpal tunnel syndrome (without thenar atrophy or spontaneous activity on electrophysiological examination of the abductor pollicis brevis (apb) muscle) exclusion criteria: * secondary entrapment neuropathies * cervical radiculopathy * systemic diseases with increased risk of the carpal tunnel syndrome * gained surgical relief of the syndrome * treated with ultrasound for the syndrome * a history of steroid injections into the carpal tunnel and of physical therapy within the last 3 months * patients with either thenar atrophy or spontaneous activity (fibrillation potentials and positive sharp waves) on electrophysiological examination

Keywords: carpal tunnel syndrome,ultrasound,pulsed ultrasound
natural history study of oculopharyngeal muscular dystrophy

Conditions: Oculopharyngeal Muscular Dystrophy

Summary: the objective of this study is to test a set of clinical outcome measures longitudinally in a cohort of opmd patients to identify ones that show quantifiable change over time as the disease progresses. the investigators' goal is to delineate the natural history of opmd.

opmd patients will undergo a screening evaluation and testing to confirm the participants carry the opmd mutation. subjects fulfilling the inclusion/exclusion criteria will be enrolled and followed prospectively at regular intervals to determine the natural history of this disease. measures of muscle function and swallowing will be made at baseline and at follow-up visits to measure natural clinical progression.

Eligibility criteria:
inclusion criteria: * opmd by genetic criteria * ≥ 18 years old * english-speaking exclusion criteria: * another medical condition that precludes safe completion of study tasks (such as severe cardiac or respiratory disease) * another medical condition that causes symptoms similar to opmd (i.e., ptosis, dysphagia \[trouble swallowing\] or limb weakness). * history of head or neck cancer, or history of radiation to the head or neck * a videofluoroscopic swallow study within the 12 months prior to study enrollment

Keywords: opmd
burn healing and analgesia with propranolol

Conditions: Burns; Pain

Summary: the purpose of this study is to investigate the ability of propranolol to decrease pain and improve recovery in burn patients with a common genotype.


Eligibility criteria:
inclusion criteria: * thermal burn * greater than or equal to 18 years of age * less than 60 years of age * able to speak and read english exclusion criteria: * intubated * clinically unstable * other substantial comorbid injury (e.g. long bone fracture) * heart block greater than first degree (ekg) * history of coronary artery disease * history of congestive heart failure * asthma (within past 10 years, induced by a beta-blocker, or receiving current treatment) * pregnant * prisoner * psychotic, suicidal, or homicidal * diabetic * hepatic failure (acute or chronic) * renal failure (acute or chronic) * history of hyperthyroidism unless taking synthroid or other thyroid hormone replacement * exceeds daily acceptable chronic opioid use prior to burn * interacting medication * received propranolol within the last 6 months * multiple severe allergic reactions * on daily methylphenidate or similar stimulant medication * unwilling to use medically acceptable birth control (if childbearing potential) * breastfeeding * severe peripheral vascular disease or vasospastic disorder * bradycardia that in the opinion of the investigator would constitute too great a risk when considered in the context of the patient's medical comorbidities and health history * other criteria that in investigator's opinion makes participant poor candidate for the trial * cancer (except basal cell cancer)

Keywords: burns pain